872 related articles for article (PubMed ID: 26214039)
1. Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease.
Hadinegoro SR; Arredondo-García JL; Capeding MR; Deseda C; Chotpitayasunondh T; Dietze R; Muhammad Ismail HI; Reynales H; Limkittikul K; Rivera-Medina DM; Tran HN; Bouckenooghe A; Chansinghakul D; Cortés M; Fanouillere K; Forrat R; Frago C; Gailhardou S; Jackson N; Noriega F; Plennevaux E; Wartel TA; Zambrano B; Saville M;
N Engl J Med; 2015 Sep; 373(13):1195-206. PubMed ID: 26214039
[TBL] [Abstract][Full Text] [Related]
2. Symptomatic Dengue in Children in 10 Asian and Latin American Countries.
L'Azou M; Moureau A; Sarti E; Nealon J; Zambrano B; Wartel TA; Villar L; Capeding MR; Ochiai RL; ;
N Engl J Med; 2016 Mar; 374(12):1155-66. PubMed ID: 27007959
[TBL] [Abstract][Full Text] [Related]
3. Effect of Dengue Serostatus on Dengue Vaccine Safety and Efficacy.
Sridhar S; Luedtke A; Langevin E; Zhu M; Bonaparte M; Machabert T; Savarino S; Zambrano B; Moureau A; Khromava A; Moodie Z; Westling T; Mascareñas C; Frago C; Cortés M; Chansinghakul D; Noriega F; Bouckenooghe A; Chen J; Ng SP; Gilbert PB; Gurunathan S; DiazGranados CA
N Engl J Med; 2018 Jul; 379(4):327-340. PubMed ID: 29897841
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of a tetravalent dengue vaccine in children in Latin America.
Villar L; Dayan GH; Arredondo-García JL; Rivera DM; Cunha R; Deseda C; Reynales H; Costa MS; Morales-Ramírez JO; Carrasquilla G; Rey LC; Dietze R; Luz K; Rivas E; Miranda Montoya MC; Cortés Supelano M; Zambrano B; Langevin E; Boaz M; Tornieporth N; Saville M; Noriega F;
N Engl J Med; 2015 Jan; 372(2):113-23. PubMed ID: 25365753
[TBL] [Abstract][Full Text] [Related]
5. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial.
Capeding MR; Tran NH; Hadinegoro SR; Ismail HI; Chotpitayasunondh T; Chua MN; Luong CQ; Rusmil K; Wirawan DN; Nallusamy R; Pitisuttithum P; Thisyakorn U; Yoon IK; van der Vliet D; Langevin E; Laot T; Hutagalung Y; Frago C; Boaz M; Wartel TA; Tornieporth NG; Saville M; Bouckenooghe A;
Lancet; 2014 Oct; 384(9951):1358-65. PubMed ID: 25018116
[TBL] [Abstract][Full Text] [Related]
6. Development of the Sanofi Pasteur tetravalent dengue vaccine: One more step forward.
Guy B; Briand O; Lang J; Saville M; Jackson N
Vaccine; 2015 Dec; 33(50):7100-11. PubMed ID: 26475445
[TBL] [Abstract][Full Text] [Related]
7. Analysis of Hospitalized and Severe Dengue Cases Over the 6 years of Follow-up of the Tetravalent Dengue Vaccine (CYD-TDV) Efficacy Trials in Asia and Latin America.
Forrat R; Dayan GH; DiazGranados CA; Bonaparte M; Laot T; Capeding MR; Sanchez L; Coronel DL; Reynales H; Chansinghakul D; Hadinegoro SRS; Perroud AP; Frago C; Zambrano B; Machabert T; Wu Y; Luedtke A; Price B; Vigne C; Haney O; Savarino SJ; Bouckenooghe A; Noriega F
Clin Infect Dis; 2021 Sep; 73(6):1003-1012. PubMed ID: 33822015
[TBL] [Abstract][Full Text] [Related]
8. Four-year safety follow-up of the tetravalent dengue vaccine efficacy randomized controlled trials in Asia and Latin America.
Arredondo-García JL; Hadinegoro SR; Reynales H; Chua MN; Rivera Medina DM; Chotpitayasunondh T; Tran NH; Deseda CC; Wirawan DN; Cortés Supelano M; Frago C; Langevin E; Coronel D; Laot T; Perroud AP; Sanchez L; Bonaparte M; Limkittikul K; Chansinghakul D; Gailhardou S; Noriega F; Wartel TA; Bouckenooghe A; Zambrano B;
Clin Microbiol Infect; 2018 Jul; 24(7):755-763. PubMed ID: 29408333
[TBL] [Abstract][Full Text] [Related]
9. Accuracy and efficacy of pre-dengue vaccination screening for previous dengue infection with five commercially available immunoassays: a retrospective analysis of phase 3 efficacy trials.
DiazGranados CA; Bonaparte M; Wang H; Zhu M; Lustig Y; Schwartz E; Forrat R; Dayan GH; Hodge S; Ataman-Önal Y; Savarino SJ
Lancet Infect Dis; 2021 Apr; 21(4):529-536. PubMed ID: 33212068
[TBL] [Abstract][Full Text] [Related]
10. Secondary Analysis of the Efficacy and Safety Trial Data of the Tetravalent Dengue Vaccine in Children and Adolescents in Colombia.
Reynales H; Carrasquilla G; Zambrano B; Cortés S M; Machabert T; Jing J; Pallardy S; Haney O; Faccini M; Quintero J; Noriega F
Pediatr Infect Dis J; 2020 Apr; 39(4):e30-e36. PubMed ID: 32040014
[TBL] [Abstract][Full Text] [Related]
11. Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial.
Sabchareon A; Wallace D; Sirivichayakul C; Limkittikul K; Chanthavanich P; Suvannadabba S; Jiwariyavej V; Dulyachai W; Pengsaa K; Wartel TA; Moureau A; Saville M; Bouckenooghe A; Viviani S; Tornieporth NG; Lang J
Lancet; 2012 Nov; 380(9853):1559-67. PubMed ID: 22975340
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of a tetravalent dengue vaccine in healthy children aged 4-16 years: a randomised, placebo-controlled, phase 3 trial.
Biswal S; Borja-Tabora C; Martinez Vargas L; Velásquez H; Theresa Alera M; Sierra V; Johana Rodriguez-Arenales E; Yu D; Wickramasinghe VP; Duarte Moreira E; Fernando AD; Gunasekera D; Kosalaraksa P; Espinoza F; López-Medina E; Bravo L; Tuboi S; Hutagalung Y; Garbes P; Escudero I; Rauscher M; Bizjajeva S; LeFevre I; Borkowski A; Saez-Llorens X; Wallace D;
Lancet; 2020 May; 395(10234):1423-1433. PubMed ID: 32197105
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of a Tetravalent Dengue Vaccine in Healthy Children and Adolescents.
Biswal S; Reynales H; Saez-Llorens X; Lopez P; Borja-Tabora C; Kosalaraksa P; Sirivichayakul C; Watanaveeradej V; Rivera L; Espinoza F; Fernando L; Dietze R; Luz K; Venâncio da Cunha R; Jimeno J; López-Medina E; Borkowski A; Brose M; Rauscher M; LeFevre I; Bizjajeva S; Bravo L; Wallace D;
N Engl J Med; 2019 Nov; 381(21):2009-2019. PubMed ID: 31693803
[TBL] [Abstract][Full Text] [Related]
14. Tetravalent Dengue Vaccine Reduces Symptomatic and Asymptomatic Dengue Virus Infections in Healthy Children and Adolescents Aged 2-16 Years in Asia and Latin America.
Olivera-Botello G; Coudeville L; Fanouillere K; Guy B; Chambonneau L; Noriega F; Jackson N;
J Infect Dis; 2016 Oct; 214(7):994-1000. PubMed ID: 27418050
[TBL] [Abstract][Full Text] [Related]
15. Assessment of the long-term efficacy of a dengue vaccine against symptomatic, virologically-confirmed dengue disease by baseline dengue serostatus.
Dayan GH; Langevin E; Gilbert PB; Wu Y; Moodie Z; Forrat R; Price B; Frago C; Bouckenooghe A; Cortes M; Noriega F; DiazGranados CA
Vaccine; 2020 Apr; 38(19):3531-3536. PubMed ID: 32204943
[TBL] [Abstract][Full Text] [Related]
16. Dependency of Vaccine Efficacy on Preexposure and Age: A Closer Look at a Tetravalent Dengue Vaccine.
Yang Y; Meng Y; Halloran ME; Longini IM
Clin Infect Dis; 2018 Jan; 66(2):178-184. PubMed ID: 29020332
[TBL] [Abstract][Full Text] [Related]
17. Bridging Efficacy of a Tetravalent Dengue Vaccine from Children/Adolescents to Adults in Highly Endemic Countries Based on Neutralizing Antibody Response.
Gilbert PB; Huang Y; Juraska M; Moodie Z; Fong Y; Luedtke A; Zhuang Y; Shao J; Carpp LN; Jackson N; Chambonneau L; Bouckenooghe A; Zambrano B; Frago C; Pallardy S; Noriega F
Am J Trop Med Hyg; 2019 Jul; 101(1):164-179. PubMed ID: 31115304
[TBL] [Abstract][Full Text] [Related]
18. Estimating the public health importance of the CYD-tetravalent dengue vaccine: Vaccine preventable disease incidence and numbers needed to vaccinate.
Gessner BD; Wilder-Smith A
Vaccine; 2016 Apr; 34(20):2397-401. PubMed ID: 27055020
[TBL] [Abstract][Full Text] [Related]
19. The Impact of the Newly Licensed Dengue Vaccine in Endemic Countries.
Aguiar M; Stollenwerk N; Halstead SB
PLoS Negl Trop Dis; 2016 Dec; 10(12):e0005179. PubMed ID: 28002420
[TBL] [Abstract][Full Text] [Related]
20. Cytokine Profile of Children Hospitalized with Virologically-Confirmed Dengue during Two Phase III Vaccine Efficacy Trials.
Harenberg A; de Montfort A; Jantet-Blaudez F; Bonaparte M; Boudet F; Saville M; Jackson N; Guy B
PLoS Negl Trop Dis; 2016 Jul; 10(7):e0004830. PubMed ID: 27459266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
